Please assess the completion status of the following clinical trial:

Trial Title: SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis Fungoides

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Biopsy-proven CTCL, MF subtype~* Clinical stage IB, II, or III, with staging based on screening assessments~* Minimum mSWAT score of 10 at screening~* Receipt of at least one prior therapy for CTCL~Key Exclusion Criteria:~* Previous enrollment in a cobomarsen study~* Prior therapy with vorinostat or other HDAC inhibitors, or contraindication to an HDAC inhibitor~* Sézary syndrome or mycosis fungoides with B2 involvement, defined as documented history of B2 and/or B2 staging at screening~* Evidence of large cell transformation~* Lymph node involvement at screening, unless radiologically or histologically confirmed to be nonmalignant~* Visceral involvement related to MF at screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cobomarsen (Type: EXPERIMENTAL): Cobomarsen will be administered by intravenous 2-hour infusion at a dose of 282 mg on Days 1, 3, 5, 8, and weekly thereafter
- Vorinostat (Type: ACTIVE_COMPARATOR): Vorinostat will be administered orally at a dose of 400 mg (four 100-mg capsules) once daily with food, at approximately the same time each day.

Based on this trial design, predict the completion outcome and termination type (if applicable).